Mr. Dable joined Acceleron in December 2016 as the Company’s President and Chief Executive Officer and member of its Board of Directors. Mr. Dable most recently served as President of U.S. Pharmaceuticals at Bayer AG. During his 22-year tenure there, Mr. Dable held positions of increasing responsibility. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head, EYLEA®, Global Head, Neurology and Ophthalmology; Vice President, Regional Head, Hematology and Cardiology; Director of International Sales and Marketing, Biologics Research; and Head of Strategic Planning, Pharmaceuticals, Japan. Mr. Dable’s earlier experience at Bayer AG includes various sales and sales management positions in Canada. As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. Mr. Dable also managed research and development collaborations and served on Joint Steering Committees with companies such as Algeta ASA, Orion Corporation and Regeneron Pharmaceuticals. Mr. Dable most recently served on the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Dable received a BBA in Marketing and Finance and his MBA from the University of New Brunswick. 

Cellular growth and repair, protein engineering, serious and rare diseases, chronic anemia, thalassemia, neuromuscular diseases